论文部分内容阅读
目的:评价替比夫定与乙肝疫苗对乙肝病毒(HBV)感染孕妇阻断母婴传播的疗效。方法:选取2014年2月—2015年2月间收治的妊娠伴有HBV感染孕妇54例,将其分成观察组和对照组,每组27例;观察组孕妇给予替比夫定与乙肝疫苗治疗,对照组患者给予复方甘草酸苷片治疗,比较两组孕妇母婴传播的阻断效果。结果:治疗后两组患者的脐带血HBV检测阳性数、12月后HBV检测阳性数经比较,后者优于前者(P<0.05);两组乙肝病毒复制数、ALT、AST和产后出血率经比较其差异均具有统计学意义(P<0.05)。结论:采用替比夫定与乙肝疫苗阻断HBV宫内传播,效果较佳,且治疗安全、可靠,能够从根本上阻断HBV母婴垂直传播。
Objective: To evaluate the efficacy of telbivudine and hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus (HBV) infection in pregnant women. METHODS: Fifty-four pregnant women with HBV infection during pregnancy from February 2014 to February 2015 were divided into observation group and control group, with 27 cases in each group. Pregnant women in observation group were treated with telbivudine and hepatitis B vaccine The patients in the control group were treated with compound glycyrrhizin tablets. The blocking effect of mother-to-child transmission in the two groups was compared. Results: After treatment, the number of positive cord blood HBV test was positive in both groups, and the positive number of HBV test after 12 months was better than the former (P <0.05). The numbers of HBV replication, ALT, AST and postpartum hemorrhage After comparing the differences were statistically significant (P <0.05). Conclusion: The use of telbivudine and hepatitis B vaccine block HBV intrauterine transmission, the effect is better, and the treatment is safe and reliable, can fundamentally block the vertical transmission of HBV mother and child.